The U.S. NIH’s COVID-19 Treatment Guidelines Panel today announced a change to its previous recommendations for COVID-19 treatments.
The purpose of this new NIH statement is to provide clinicians with guidance on the role of bebtelovimab a U.S. FDA Authorized monoclonal antibody treatment, as an additional option for this patient population.
Read More